Breaking News Headlines Today | Ground News

See every side of every news story

endpoints.news image

News from endpoints.news

endpoints.news’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

endpoints.news’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about endpoints.news

Where is endpoints.news located?endpoints.news's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top endpoints.news News

New Menopause Drug to Target Hot Flashes without Hormones Gets FDA Approval

FDA · United States

New Menopause Drug to Target Hot Flashes without Hormones Gets FDA Approval

89% Center coverage: 46 sources

By Jacqueline Howard, CNN (CNN) — The US Food and Drug Administration has approved another once-a-day pill that works without hormones to treat moderate to severe hot flashes in menopausal women, drugmaker Bayer said Friday. The drug, elinzanetant, is expected to be available in the United States beginning in November under the brand name Lynkuet, Bayer said. It works by blocking the brain chemicals responsible for hot flashes and night sweats –…See the Story

Novartis to acquire Avidity Biosciences for about $12 billion — REUTERS / ixx511

Business · United States

Novartis to acquire Avidity Biosciences for about $12 billion

44% Center coverage: 34 sources

Lilly to Acquire Adverum Biotechnologies

Eli Lilly · United States

Lilly to Acquire Adverum Biotechnologies

75% Center coverage: 4 sources

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal...See the Story

Breaking News Topics Related to endpoints.news